Thailand's Cannabis U-Turn Is Reshaping Southeast Asia's CBD Trade

October 24, 2026

Photo via Unsplash.

Four years ago, Thailand did something no other Asian nation had done: it pulled cannabis off the narcotics list entirely, and within months Bangkok's tourist strips were thick with dispensary neon and budtenders hawking pre-rolls to backpackers. That was June 2022. By June 2025, the same government had reclassified cannabis flower as a controlled herb, and by September 2026, the Cabinet had approved a bill that would confine cannabis to medical use only, closing the loophole that let recreational sale flourish in the first place. On paper, that reads like a classic boom-bust prohibition story. It isn't, and the distinction matters enormously for anyone tracking where cannabis and CBD material actually moves in the region.

Cannabis never went back to Category 5 narcotics status in Thailand. That's not a technicality -- it's the hinge the whole supply chain is swinging on. A full re-criminalization sends growers, processors, and capital fleeing a market outright, the way it has in countries that reverse legalization completely. A narrowing toward medical-only status with a managed compliance runway does something different: it squeezes out the undercapitalized retail operators while leaving a lane open for the growers and processors who can meet certification standards. The licensing data from late 2025 and early 2026 shows that squeeze happening in real time -- outlet counts collapsing, export-grade certification staying scarce, foreign ownership getting carved out of extraction specifically.

The mid-term question worth asking isn't whether Thailand's cannabis industry survives. Some version of it clearly will. The question is whether it survives as the regional hub it looked poised to become in 2022, or whether the compliance squeeze pushes CBD and hemp material sourcing toward neighbors like Vietnam and Laos, leaving Thailand to hold a smaller, higher-margin medical-export niche. The licensing numbers, trade data, and pending legislation all point toward an answer -- just not a tidy one.

From Asia's First Green Light to a Narrowing Door

The timeline here is worth laying out precisely, because each step changed the legal mechanism in a different way, and the mechanism is what determines how supply chains respond. On June 9, 2022, Thailand's Ministry of Public Health formally delisted cannabis from the narcotics schedule, making it the first country in Asia to do so. What followed was fast and largely unregulated: dispensaries opened by the thousands, tourism operators folded cannabis cafes into Bangkok and Phuket itineraries, and estimates of outlet counts climbed into the thousands of storefronts nationwide within about two years.

That open-market phase ended on June 26, 2025, when Public Health Minister Somsak Thepsuthin signed a ministerial notification reclassifying cannabis flower as a controlled herb under the Traditional Medicine Act. Published in the Royal Gazette with immediate effect, the notification didn't touch cannabis's status on the narcotics schedule -- it stayed off Category 5. What it did was end open recreational sale and purchase, requiring medical justification and tighter point-of-sale controls while keeping penalties well below what a narcotics offense would carry. That's the legal nuance that gets lost in a lot of coverage: Thailand tightened access without reversing the underlying scheduling decision, which is a meaningfully softer landing than the re-criminalization language implies.

The next shoe dropped in late September 2026, when the Cabinet approved a bill limiting cannabis strictly to medical use, closing the loophole the 2022 decriminalization had left wide open. Public Health Minister Pattana Promphat announced the bill after a round of public hearings, framing it as a correction rather than a reversal. The bill bans advertising outright and introduces criminal penalties for noncompliance -- a real enforcement upgrade from the administrative notifications of 2025. But it also gives existing dispensaries until 2028 to come into full compliance, which is the detail that separates this from an overnight shutdown. Operators get roughly eighteen months to either restructure toward medical supply, pivot to export-grade cultivation, or wind down. That runway is exactly what a shrinking but still-functioning industry needs to reorganize around new rules instead of collapsing under them.

The 2026 Licensing Squeeze, By the Numbers

Thailand's cannabis outlet count is set to drop sharply from a peak of 18,433 in December 2025, as 8,636 licenses face expiry and only 1,339 renewals have been approved so far—leaving roughly 11,136 outlets still active.

If the legislative timeline tells you Thailand is narrowing its cannabis market rather than killing it, the licensing data tells you how fast and how unevenly that narrowing is happening. On April 26, 2026, a Narcotics Code extract regulation took effect that tightened who could legally process cannabis extracts -- a direct shot at the processing layer of the supply chain rather than cultivation or retail. Four days later, Ministerial Regulation No. 2 B.E. 2569 was published, establishing a four-criteria licensing gate that controlled-herb premises now have to clear to keep operating legally.

One provision stands out for anyone watching international capital flows: foreign-owned entities are now excluded from extract production specifically. That hits a real, identifiable group -- international cannabis and CBD companies that had set up Thai subsidiaries over the prior three years precisely to get extraction capacity inside the market. Those structures now need to be rethought, not abandoned, since the exclusion targets extraction rather than cultivation or export licensing broadly.

Then comes the renewal cliff. Existing licenses were set to expire December 31, 2026, forcing every operator -- including those supplying buyers outside Thailand -- through a fresh approval gate under the new rules. The early data on how that's gone is stark. By late December 2025, of 8,636 outlets facing license expiration, only 1,339 were renewed -- a 15.5% renewal rate -- while 7,297 shut down. That left roughly 11,136 active dispensaries nationwide, down from a peak of 18,433. That's not a trim; it's a sharp contraction in outlet count inside about a year, concentrated almost entirely among smaller, retail-era operators who lacked the capital or compliance infrastructure to clear the new bar.

The certification picture at the cultivation end is even tighter. As of February 13, 2026, only 217 farms held GACP export certification, against more than 11,800 legacy license holders from the 2022-era boom. That's under 2% of the legacy base meeting export-grade standards. Whatever Thailand's cannabis industry looks like in 2028, it's going to be built around that small certified core, not the thousands of operators who entered during the open-retail years.

Why Export-Grade Medical Supply Is Surviving the Retail Crash

Here's the pattern that doesn't show up if you only look at outlet counts: Thailand's commercial medical-export pipeline hasn't contracted the way the retail dispensary market has. While storefronts closed by the thousands through 2025 and 2026, the certified export segment has held relatively steady, pointing to a real split between two markets that used to get lumped together under one decriminalized umbrella -- the consumer-facing storefront business and the compliance-heavy pipeline feeding regulated buyers abroad.

GACP certification is the mechanism doing most of the sorting. It's not a Thai-specific bureaucratic hurdle invented for this crackdown -- it's a widely recognized agricultural standard that regulated buyers in the EU and elsewhere in Asia already use to vet cannabis and hemp suppliers. What's happening in Thailand is that GACP status, rather than domestic retail licensing, is becoming the real gate for who gets to sell into serious international markets. A dispensary license got you into Bangkok's retail scene during the boom years; it was never going to get raw material past a European import inspector.

Read alongside the foreign-ownership exclusion from extraction specifically -- not cultivation, not export licensing broadly -- a reasonably coherent government strategy comes into view: keep raw and certified material flowing outward, but keep the value-added processing step domestic. That's a familiar move for a government trying to protect downstream margin capture while still opening (or at least not closing) the upstream door to foreign buyers and growers. Colombia ran a comparable playbook in its early medical cannabis framework, drawing a line between flower and biomass export, which it allowed relatively early, and domestic extraction and processing, which it restricted more tightly to protect local industry development. Thailand's rules aren't identical, but the underlying logic -- export the plant, process it at home -- rhymes.

The honest counter-case is scale. Two hundred seventeen certified farms is a small base to build a regional supply hub on. If international buyers need consistent volume and predictable harvest cycles across multiple seasons -- which most contracted B2B buyers do -- a certified base this thin may not be deep enough to absorb demand growth without significant new certification throughput, something the current licensing bottleneck isn't obviously built to accelerate.

The Regional Map: Who's Positioned to Absorb the Spillover

Zoom out to the region and the picture sorts into three distinct postures rather than a single trend. Cambodia is the clean no. Its 1997 Law on Drug Control still prohibits cultivation, sale, and possession of cannabis in any form as of May 2026, with zero tolerance for unauthorized imports. There's no visible near-term legislative pathway for Cambodia to absorb displaced Thai supply or capital, and nothing in its policy history suggests that's about to change on a mid-term horizon.

Vietnam and Laos look like a different story, but not the one some observers expected. Neither is positioning as a cannabis competitor to Thailand -- both are instead emerging as hemp-seed trade partners. Vietnam was Thailand's number-two destination and origin partner for hemp seed in 2024 trade data, which points toward a regional supply chain that's splitting by product category rather than consolidating around one country. Thailand holds the cannabis extraction and medical-export niche; Vietnam and Laos build out industrial hemp seed and fiber trade alongside it. That's a bifurcated supply chain, not a relocated one -- displaced Thai retail capital isn't likely to simply reappear as Vietnamese cannabis cultivation, because Vietnam's regulatory apparatus isn't built around cannabis flower or extract the way Thailand's is.

The wild card is Thailand's own pending Cannabis and Hemp Act, which was in final pre-parliament consultation as of June 2026. If passed, it would supersede the current patchwork of ministerial notifications and regulations with comprehensive legislation -- potentially creating export pathways clear and durable enough for international buyers to actually underwrite contracts against, rather than hedging against the next ministerial reclassification.

There's real precedent for reasoning that this kind of messy middle period eventually resolves into something more bankable. Other countries that have gone through rounds of ministerial and regulatory patchwork have eventually arrived at comprehensive cannabis legislation that locked in rules investors could plan multi-year positions around. Thailand looks to be tracing a similar arc, compressed into a shorter window and bending toward medical/export use rather than broad legalization. But that comparison comes with a serious caveat worth sitting with: final pre-parliament consultation status is not passage, and it's certainly not a fixed timeline. Thai cannabis policy has already reversed direction twice in four years. Betting on a third act playing out exactly as drafted would ignore that history rather than learn from it.

What This Means for Buyers and Investors Over the Next 3-7 Years

For buyers and investors trying to plan three to seven years out, the near-term phase -- through the 2028 compliance deadline -- is the one with the clearest signal. Expect continued consolidation among Thai operators as that deadline approaches, with the advantage accruing to larger, better-capitalized, GACP-certified growers over the small retail-era operators who dominated the 2022-2024 boom. The renewal data from the 2026 licensing cliff is already a preview of this: 15.5% survival rates don't reverse themselves, they compound, as remaining capital and certification infrastructure concentrate in fewer hands.

Foreign companies that built Thai subsidiaries specifically to own extraction capacity need new structures now, not in 2028. The foreign-ownership exclusion from extract production makes direct ownership untenable, which points toward raw material supply contracts or licensing partnerships with domestic processors as the more durable model going forward -- buy certified biomass or extract from a Thai-owned, GACP-certified operator rather than trying to own the extraction line outright.

Two branching paths matter most from here. If the Cannabis and Hemp Act passes largely intact, it could formalize export licensing in a way that actually increases foreign capital access to cultivation and certification, even while recreational retail stays permanently closed. That would harden the medical/industrial split rather than resolve it toward either full liberalization or full prohibition -- a stable equilibrium investors could underwrite. If the Act stalls, gets diluted in parliament, or gets shelved the way plenty of pending Thai legislation has before, expect continued governance by ministerial notification, which keeps the market volatile on a rolling basis. That volatility is exactly what pushes risk-averse buyers to diversify sourcing toward Vietnam and Laos hemp seed rather than commit supply chains to Thai cannabis extract indefinitely.

It's worth being blunt about the limits of this forecast. Everything here is reasoned extrapolation from current licensing data, trade figures, and the regional legal landscape -- not a guaranteed trajectory. Thailand's two policy reversals in four years are themselves the strongest evidence against confident timeline predictions. Anyone sourcing from or investing in this market over the next several years should treat the 2028 deadline and the Act's parliamentary fate as the two checkpoints to watch, and build contingency into sourcing plans rather than assuming either outcome.

Strip away the headlines about Thailand reversing course on cannabis, and what's actually visible in the licensing data is a government narrowing deliberately toward a licensed medical-export model rather than stumbling back toward prohibition. Cannabis staying off the narcotics schedule through three straight policy changes -- 2022 decriminalization, 2025 reclassification, 2026 medical-only bill -- is the detail that keeps getting lost, and it's the one that tells you this is contraction and redirection, not retreat. The 2028 compliance deadline is the next real inflection point, the moment the managed wind-down either completes cleanly or reveals how much of the retail-era industry actually made the transition to certified medical supply.

If there's one number from this whole story worth remembering over any single piece of legislation, it's under 2% -- the share of legacy license holders that currently hold GACP export certification. Laws can be redrafted, ministerial notifications can be reissued, and the Cannabis and Hemp Act may pass, stall, or get watered down in ways nobody can forecast with confidence today. But the certification bottleneck is an operational reality that doesn't move on a legislative calendar. Whoever clears that bar controls Thailand's export-facing supply for years regardless of what parliament does next.

The likeliest shape of Southeast Asia's CBD and hemp supply chain over the next several years isn't Thailand-centric the way it looked in 2022 -- it's multi-node. Medical-grade cannabis extract concentrated in a small, certified Thai core; industrial hemp seed and fiber building out through Vietnam and Laos; Cambodia sitting on the sidelines entirely. That split could still harden or loosen depending on whether Thailand's pending Act genuinely reopens foreign investment in cultivation and certification. Until that bill clears parliament in some recognizable form, the safest assumption for buyers is that the region's supply chain stays divided by product category rather than consolidated under any single country's rules.